A detailed history of Man Group PLC transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Man Group PLC holds 21,653 shares of ITOS stock, worth $168,243. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,653
Holding current value
$168,243
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.09 - $17.97 $218,478 - $389,104
21,653 New
21,653 $221,000
Q4 2023

Feb 14, 2024

BUY
$8.57 - $11.06 $85,742 - $110,655
10,005 New
10,005 $109,000
Q4 2022

Feb 14, 2023

SELL
$17.77 - $21.6 $547,724 - $665,776
-30,823 Reduced 26.44%
85,756 $1.67 Million
Q3 2022

Nov 14, 2022

SELL
$18.6 - $27.25 $452,538 - $662,992
-24,330 Reduced 17.27%
116,579 $2.22 Million
Q2 2022

Aug 15, 2022

BUY
$16.57 - $35.1 $386,462 - $818,637
23,323 Added 19.83%
140,909 $2.9 Million
Q1 2022

May 16, 2022

BUY
$31.92 - $47.45 $3.13 Million - $4.65 Million
97,985 Added 499.9%
117,586 $3.78 Million
Q4 2021

Feb 14, 2022

SELL
$26.23 - $47.86 $191,505 - $349,425
-7,301 Reduced 27.14%
19,601 $913,000
Q3 2021

Nov 15, 2021

BUY
$23.91 - $29.58 $86,649 - $107,197
3,624 Added 15.57%
26,902 $726,000
Q2 2021

Aug 16, 2021

SELL
$17.9 - $36.1 $34,457 - $69,492
-1,925 Reduced 7.64%
23,278 $597,000
Q1 2021

May 17, 2021

SELL
$30.86 - $44.2 $83,352 - $119,384
-2,701 Reduced 9.68%
25,203 $861,000
Q4 2020

Feb 16, 2021

SELL
$21.59 - $33.95 $270,285 - $425,020
-12,519 Reduced 30.97%
27,904 $944,000
Q3 2020

Nov 16, 2020

BUY
$17.57 - $32.92 $710,232 - $1.33 Million
40,423 New
40,423 $997,000

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $276M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.